

Enantioselective Total Synthesis of (+)-Hinckdentine A via a Catalytic Dearomatization Approach

Kazuya Douki,^{§,†} Hiroyuki Ono,^{§,‡} Tohru Taniguchi,[⊥] Jun Shimokawa,[†] Masato Kitamura,^{*,†} and Tohru Fukuyama^{*,†}

[†]Graduate School of Pharmaceutical Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

[‡]Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

[⊥]Faculty of Advanced Life Science, Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan


S Supporting Information

ABSTRACT: Optically pure hinckdentine A was synthesized on a 300 mg scale via an asymmetric catalysis-based strategy. The key steps to the first asymmetric synthesis involved (i) enantioselective dearomative cyclization of an achiral *N*-acyl indole that allowed for the efficient construction of the key polycyclic indoline intermediate with a crucial tetrasubstituted stereogenic carbon center, (ii) Beckmann fragmentation-mediated ring expansion, (iii) rearrangement-based introduction of an anilinic nitrogen atom, (iv) regioselective tribromination, and (v) final closure of the cyclic amidine moiety.

Rapid construction of architecturally complex polycyclic systems is one of the most important frontiers in the field of natural products/pharmaceuticals synthesis.¹ A potent solution to this challenging mission is a dearomatization strategy wherein a functionalized planar aromatic framework acquires a three-dimensional character. Catalytic asymmetric dearomative cyclization is particularly attractive for the efficient construction of chiral polycyclic systems. Substantial efforts have been devoted to this field² after the pioneering works of Buchwald,³ Bedford,⁴ and You.⁵ These dearomatization strategies have been applied to the synthesis of a variety of natural products and demonstrated their potential for constructing complex structures with rich sp³ architectures.⁶ It occurred to us that the application of this strategy could be advantageous in the synthesis of the screw-shaped hinckdentine A (**1**), which was isolated from the marine bryozoan *Hincksinoflustra denticulata* in 1987.⁷ The structure, unambiguously determined by single X-ray crystallographic analysis, is characterized by a highly brominated indolo[1,2-*c*]quinazoline core fused to a seven-membered lactam unit through the consecutive stereogenic centers at C12 and C17a, and a cyclic amidine moiety. The biological activities of this compound have not been reported due to a shortage of **1** isolated from natural sources. A synthetic supply of this material,⁸ therefore, is clearly important for uncovering the biological activity of **1** and its derivatives.⁹

Scheme 1 shows our retrosynthetic analysis of **1**. McWhorter's synthetic study^{8b} indicated that the C8-selective bromination of 8-desbromohinckdentine A would be problematic, giving an

Scheme 1. Retrosynthetic Analysis




inseparable mixture of various tribromides and tetrabromides. Accordingly, Kawasaki employed a protected cyclic aminal intermediate for selective tribromination, leading to the sole example of a racemic total synthesis.¹⁰ We thus selected the indoline/anilide **2** as our key intermediate. Compound **2** was expected to favor *ortho*–*para*-dibromination at C8 and C10 on the left-hand indoline as well as single *para*-bromination at C2 on the right-hand anilide. The dearomatized indole **2**, in which an aromatic moiety was wedged into the indole 2-position at C17a, could be disconnected to form two planar synthons **3** and **4** on the basis of an asymmetric dearomative coupling. The nitrogen functionalities in the azepanone moiety in **3** and the acylamino group in **4** were retrosynthetically excised. The simple *N*-acyl tetrahydrocarbazole **5** was thus chosen for the execution of a pivotal asymmetric dearomative cyclization.

First, the palladium-catalyzed asymmetric dearomative Heck-type cyclization of **5** to **6** was investigated. Table 1 summarizes the results. The substrate **5** was prepared in 89% yield in two steps from the known 5-oxo-tetrahydrocarbazole ethylene ketal.^{11,12} A nonasymmetric variant using the related *N*-acyl indoles have been reported originally by Grigg¹³ in 2001 and later developed by Wu,¹⁴ Jia,¹⁵ and Lautens.¹⁶ We attempted to render the reaction asymmetric by using an appropriate chiral ligand. Extensive investigations revealed that Feringa's phosphoramidite ligands **7**¹⁷ gave the most promising results.

Received: September 30, 2016

Published: October 22, 2016


Table 1. Palladium-Catalyzed Dearomative Cyclization and Optimization of the Reaction Conditions^a


entry	ligand	solvent	NMR yield ^b	er ^c
1	7a	<i>t</i> -BuOH	94	70/30
2	7b	<i>t</i> -BuOH	95	88/12
3	7c	<i>t</i> -BuOH	99	93/7
4	7d	<i>t</i> -BuOH	99	66/34
5	7c	DMA	99	67/33
6	7c	DMSO	93	68/32
7	7c	1,4-dioxane	47	91/9
8	7c	CH ₃ CN	43	85/15
9	7c	1,2-dichloroethane	38	86/14
10	7c	toluene	16	93/7

^aAll reactions were carried out under standard reaction conditions: **5** (100 μmol), Pd₂(dba)₃·CHCl₃ (2.5 mol %), **7** (25 mol %), NaOAc (1.5 equiv), solvent (1.5 mL), 100 °C, 18 h. ^bDetermined by ¹H NMR analysis using dimethyl sulfone as an internal standard. ^cThe enantiomeric ratio (er) was determined by HPLC analysis on DAICEL CHIRALCEL OJ-H (*n*-hexane/*i*-PrOH = 60:40; 1.0 mL/min).

The reactivity and enantioselectivity were optimized by fixing the standard conditions as follows: **5** (100 μmol), Pd₂(dba)₃·CHCl₃ (2.5 mol %), ligand **7** (25 mol %), NaOAc (1.5 equiv), *t*-BuOH (1.5 mL), temp 100 °C, and time 18 h. Among the ligands tested (**7a–d**), the phenyl-substituted ligand **7c** gave the best enantioselectivity (entries 1–4). In DMA and DMSO, the selectivity decreased (entries 5 and 6). The reactivity decreased when 1,4-dioxane, CH₃CN, or 1,2-dichloroethane was used as the solvent (entries 7–9), and the reaction was sluggish in toluene (entry 10). Our preliminary experiments on the application to other substrates also afforded the dearomatized products with good enantiomeric ratio.¹⁸ The absolute stereochemistry of the major enantiomer of **6** obtained through the use of (*S,R,R*)-**7c** was determined to be *S* by comparing the calculated and observed CD/VCD spectra.^{19,20}


With the optimized reaction conditions (entry 3) in hand, we turned to synthetic studies of **1** from the chiral intermediate **6** bearing the crucial tetrasubstituted stereogenic carbon center (Scheme 2). The synthesis of the natural enantiomer of hinckdentine A (**1**) required the (*R*)-**6** intermediate. Thus, the enantiomeric ligand (*R,S,S*)-**7c** was employed. The reproducibility of the optimized conditions was confirmed on a 10 g scale (98% isolated yield, *R/S* = 93:7). Subsequent transformations from **6** to **11** represented the ring expansion of the cyclohexenone moiety via the introduction of a nitrogen atom. Our initial attempts at the Beckmann rearrangement via the corresponding oxime tosylate afforded the complex mixture, which may indicate the increased donation from the amide nitrogen electron pair compared to the case of McWhorter's.^{8b,16a} Therefore, the Beckmann fragmentation strategy was employed. An oxime functionality was introduced at the α-position of the ketone by treatment of the intermediary silyl enolate with NOCl

Scheme 2. Construction of Seven-Membered Lactam^a

^aReagents and conditions: (a) Pd₂(dba)₃·CHCl₃ (2.5 mol %), (*R,S,S*)-**7c** (25 mol %), NaOAc (1.5 equiv), *t*-BuOH, 100 °C, 18 h, 98%, 93:7 er; (b) LHMDS, TMSCl, THF, −78 °C, 1 h, then NOCl, 3 h, 79%; (c) SOCl₂, 1,2-dichloroethane, 0 °C to rt, 1 h, then CF₃CH₂OH, 40 °C, 22 h, 77%; (d) H₂ (1 atm), Pd/C (10 mol %), EtOAc, 40 °C, 17 h, 98%, washing with ice-cold EtOH, 81%, >99:1 er; (e) H₂ (50 atm), Raney Ni, TFA, *t*-BuOH, 80 °C, 22 h, then NaHCO₃ aq, CH₂Cl₂, 40 °C, 18 h, 84% (2 steps). dba = dibenzylidene acetone, TFE = 2,2,2-trifluoroethyl.

that was generated in situ from TMSCl and *i*-AmONO.²¹ The Beckmann fragmentation of **8** was efficiently mediated by SOCl₂ and subsequent treatment with CF₃CH₂OH gave a 1:11 *E/Z* mixture of the α,β-unsaturated 2,2,2-trifluoroethyl esters **9** bearing a cyanomethyl group at C17a. Catalytic hydrogenation of **9** occurred from the face opposite to the cyanomethyl group with perfect diastereoselectivity, giving **10**²² in 98% with 93:7 er. The enantiomerically pure **10** was then obtained in 81% yield simply by rinsing the crystals with ice-cold ethanol. The heterochiral racemic crystals of **10** appear to be more soluble than the homochiral crystals. The nitrile functionality in **10** was hydrogenated on Raney nickel to provide the corresponding amine, which spontaneously reacted with the 2,2,2-trifluoroethyl ester group to give the seven-membered lactam intermediate **11**.

The remaining obstacles to be cleared toward **1** involved the conversion of **11** to the indoline/anilide intermediate corresponding to **2**, prior to the selective tribromination and formation of the amidine moiety. The solutions are illustrated in Scheme 3. Reduction of the tertiary amide functionality in **11** was attained by a modified Soai's method²³ (NaBH₄–CH₃OH–THF), leaving the secondary amide of the seven-membered lactam intact to give the amino alcohol **12** in 78% yield. After protection of the amino alcohol moiety as a TFA amide and TES ether, the resulting **13** was oxidized with Jones reagent to provide an aldehyde, which was immediately transformed to the aldoxime **14**, setting the stage for the modified Kim's protocol.²⁴ Conversion of **14** to the nitrile oxide in situ, followed by the reaction with tetrahydro-2-pyrimidinethione (**15**) afforded the cycloaddition/rearrangement product, isothiocyanate **16**, as a sole product in 72% yield from **13**. The TFA group in **16** thus obtained was too labile under basic conditions, readily forming the cyclic thiourea **17**. Extensive

Scheme 3. Total Synthesis of Hinckdentine A^a

^aReagents and conditions: (a) NaBH_4 (50 equiv), CH_3OH , THF , 65 °C, 10 h, 78%; (b) TESCl , pyridine , CH_2Cl_2 , 0 °C, 30 min, then TFAA , 0 °C, 30 min, 70%; (c) Jones reagent, acetone, 0 °C, 1 h; (d) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaOAc , EtOH , 0 °C, 1 h; (e) NCS , DMF-THF , 65 °C, 15 min, then tetrahydro-2-pyrimidinethione (**15**), Et_3N , 0 °C, 1 h, 72% (3 steps); (f) KSAc (5.0 equiv), CH_3OH , 40 °C, 4 h, then NaHCO_3 aq, rt; (g) Br_2 (3.0 equiv), CH_3NO_2 , -20 °C to rt, 30 min, then Br_2 (8.0 equiv) rt, 1.5 h, then 2-methyl-2-butene, 0 °C, 64% (2 steps); (h) $\text{HC}(\text{OCH}_3)_3$ (50 equiv), TFA (50 equiv), rt, 30 min, then $\text{CH}_3\text{OH-H}_2\text{O}$, rt, 88%. TES = triethylsilyl, TFAA = trifluoroacetic anhydride, NCS = *N*-chlorosuccinimide.

screening of the reaction conditions revealed that the premature removal of the TFA group could be suppressed by the initial treatment of **16** with KSAc ²⁵ in CH_3OH at 40 °C for 4 h, followed by a hydrolytic workup with NaHCO_3 aq. While the indoline/acetanilide intermediate **18** thus obtained was equipped with the electronic properties required for the crucial tribromination, the bromination was difficult at best probably due to the low solubility of **18** as well as the brominated intermediates in the solvents typically used for bromination (CH_2Cl_2 , CHCl_3), resulting in a facile cyclization to a methylquinazoline **19**, even at room temperature. Fortunately, the undesired pathway was suppressed by employing CH_3NO_2 as the solvent. Treatment of a clear solution of **18** in CH_3NO_2 at -20 °C with 3.0 equiv of Br_2 resulted in selective bromination at C2 and C10. Further bromination with 8.0 equiv of Br_2 at room temperature proceeded at C8 without forming the byproduct **19**. The reaction was quenched with 2-methyl-2-butene to circumvent oxidative N–N bond formation, furnishing the penultimate tribromide **20** in 64% yield from the isothiocyanate **16** in a reproducible manner.²⁶ Finally, the amidine moiety of **1** was constructed in 88% yield by treating **20** with an excess amount of $\text{HC}(\text{OCH}_3)_3$ (50 equiv) and TFA (50 equiv), presumably

via in situ removal of the acetyl group from the amidinium intermediate **21**. This final process provided hinckdentine A (**1**) on a 300 mg scale: $[\alpha]_{\text{D}}^{20} + 274$ ($c = 1.00$, CHCl_3).

In conclusion, we have achieved the first enantioselective total synthesis of hinckdentine A (**1**) in 14 steps and in 8.8% total yield from the readily available **5**, establishing the basis for future biological studies. Our unique synthetic strategy consisted of five effective key processes: (i) palladium-catalyzed asymmetric dearomative cyclization of **5** to **6**, (ii) Beckmann fragmentation/lactamization sequence leading to the seven-membered lactam **11**, (iii) rearrangement-based introduction of a nitrogen atom into the anilide **18**, (iv) regioselective tribromination, and (v) the formation of the amidine moiety to afford the indolo[1,2-*c*]quinazoline core. These processes eventually realized a 300 mg scale total synthesis of **1**. Further optimization of the present catalytic dearomatization, a mechanistic study, and applications of the key reaction to other synthetic targets are currently underway in our group.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.6b10237.

Experimental procedures, spectroscopic data, and ¹H and ¹³C NMR spectra (PDF)
 Crystallographic data of **10** (CIF)

■ AUTHOR INFORMATION

Corresponding Authors

*kitamura@os.rcms.nagoya-u.ac.jp

*fukuyama@ps.nagoya-u.ac.jp

Author Contributions

[§]These authors contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the Kato Memorial Bioscience Foundation, a Mitsubishi Tanabe Pharma Award in Synthetic Organic Chemistry, Japan, JSPS KAKENHI Grant Numbers 23590003, 25221301, 15H05641, the Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Advanced Catalytic Transformation Program for Carbon Utilization (ACT-C) from the Japan Science and Technology Agency (JST). The authors thank Mr. Yutaro Saito and Mr. Shin Suzuki (Nagoya University) for their assistance with the UltraCOOL Probe NMR facilities. The authors thank Mr. Kazuyuki Higashita (Nagoya University) for his support in X-ray crystallographic analysis.

■ REFERENCES

- (1) Lovering, F.; Bikker, J.; Humblet, C. *J. Med. Chem.* **2009**, *52*, 6752.
- (2) (a) Pape, A. R.; Kaliappan, K. P.; Kündig, E. P. *Chem. Rev.* **2000**, *100*, 2917. (b) Pouységu, L.; Deffieux, D.; Quideau, S. *Tetrahedron* **2010**, *66*, 2235. (c) Zhuo, C.-X.; Zhang, W.; You, S.-L. *Angew. Chem., Int. Ed.* **2012**, *51*, 12662. (d) Ding, Q.; Ye, Y.; Fan, R. *Synthesis* **2013**, *45*, 1. (e) Zhuo, C.-X.; Zheng, C.; You, S.-L. *Acc. Chem. Res.* **2014**, *47*, 2558. (f) Ding, Q.; Zhou, X.; Fan, R. *Org. Biomol. Chem.* **2014**, *12*, 4807. (g) Roche, S. P.; Tendoung, J.-J. Y.; Tréguier, B. *Tetrahedron* **2015**, *71*, 3549. (h) Sun, W.; Li, G.; Hong, L.; Wang, R. *Org. Biomol.*

Chem. **2016**, *14*, 2164. (i) Wu, W.-T.; Zhang, L.; You, S.-L. *Chem. Soc. Rev.* **2016**, *45*, 1570.

(3) (a) García-Fortanet, J.; Kessler, F.; Buchwald, S. L. *J. Am. Chem. Soc.* **2009**, *131*, 6676. (b) Rousseaux, S.; García-Fortanet, J.; Del Aguila Sanchez, M. A.; Buchwald, S. L. *J. Am. Chem. Soc.* **2011**, *133*, 9282.

(4) (a) Bedford, R. B.; Butts, C. P.; Haddow, M. F.; Osborne, R.; Sankey, R. F. *Chem. Commun.* **2009**, 4832. (b) Bedford, R. B.; Fey, N.; Haddow, M. F.; Sankey, R. F. *Chem. Commun.* **2011**, 47, 3649.

(5) (a) Wu, K.-J.; Dai, L.-X.; You, S.-L. *Org. Lett.* **2012**, *14*, 3772.

(b) Wu, K.-J.; Dai, L.-X.; You, S.-L. *Chem. Commun.* **2013**, 49, 8620.

(c) Xu, R.-Q.; Gu, Q.; Wu, W.-T.; Zhao, Z.-A.; You, S.-L. *J. Am. Chem. Soc.* **2014**, *136*, 15469.

(6) Roche, S. P.; Porco, J. A., Jr. *Angew. Chem., Int. Ed.* **2011**, *50*, 4068.

(7) Blackman, A. J.; Hambley, T. W.; Picker, K.; Taylor, W. C.; Thirarasana, N. *Tetrahedron Lett.* **1987**, *28*, 5561.

(8) (a) Domon, L.; Le Coeur, C.; Grelard, A.; Thiery, V.; Besson, T. *Tetrahedron Lett.* **2001**, *42*, 6671. (b) Liu, Y.; McWhorter, W. W., Jr. *J. Am. Chem. Soc.* **2003**, *125*, 4240. (c) Mendiola, J.; Castellote, I.; Alvarez-Builla, J.; Fernández-Gadea, J.; Gómez, A.; Vaquero, J. J. *J. Org. Chem.* **2006**, *71*, 1254. (d) Baeza, A.; Mendiola, J.; Burgos, C.; Alvarez-Builla, J.; Vaquero, J. J. *Eur. J. Org. Chem.* **2010**, *2010*, 5607. (e) Li, L.; Han, M.; Xiao, M.; Xie, Z. *Synlett* **2011**, *2011*, 1727. (f) Sang, P.; Xie, Y.; Zou, J.; Zhang, Y. *Org. Lett.* **2012**, *14*, 3894. (g) Morón, M.; Burgos, C.; Alvarez-Builla, J.; Salgado, A.; Mosquera, M. E. G.; Vaquero, J. J. *Chem. Commun.* **2012**, 48, 9171. (h) Rueping, M.; Rasappan, R.; Raja, S. *Helv. Chim. Acta* **2012**, *95*, 2296.

(9) The core indolo[1,2-*c*]quinazoline is known as a substructure of certain artificial biological active compounds. (a) Rohini, R.; Shanker, K.; Reddy, P. M.; Sekhar, V. C.; Ravinder, V. *Arch. Pharm. Chem. Life Sci.* **2009**, *342*, 533–540. (b) Rohini, R.; Reddy, P. M.; Shanker, K.; Hu, A.; Ravinder, V. *J. Braz. Chem. Soc.* **2010**, *21*, 897–904.

(10) Higuchi, K.; Sato, Y.; Tsuchimochi, M.; Sugiura, K.; Hatori, M.; Kawasaki, T. *Org. Lett.* **2009**, *11*, 197.

(11) Liu, P.; Wang, J.; Zhang, J.; Qiu, F. G. *Org. Lett.* **2011**, *13*, 6426.

(12) See the [Supporting Information](#) for a detailed description of the synthetic procedure.

(13) Brown, S.; Clarkson, S.; Grigg, R.; Thomas, W. A.; Sridharan, V.; Wilson, D. M. *Tetrahedron* **2001**, *57*, 1347.

(14) Zhao, L.; Li, Z.; Chang, L.; Xu, J.; Yao, H.; Wu, X. *Org. Lett.* **2012**, *14*, 2066.

(15) Shen, C.; Liu, R.-R.; Fan, R.-J.; Li, Y.-L.; Xu, T.-F.; Gao, J.-R.; Jia, Y.-X. *J. Am. Chem. Soc.* **2015**, *137*, 4936.

(16) (a) Petrone, D. A.; Yen, A.; Zeidan, N.; Lautens, M. *Org. Lett.* **2015**, *17*, 4838. (b) Petrone, D. A.; Kondo, M.; Zeidan, N.; Lautens, M. *Chem. - Eur. J.* **2016**, *22*, 5684.

(17) Teichert, J. F.; Feringa, B. L. *Angew. Chem., Int. Ed.* **2010**, *49*, 2486.

(18) See the [Supporting Information](#) for the results on two more substrates.

(19) See the [Supporting Information](#) for the experimental details.

(20) (a) Polavarapu, P. L. *Chem. Rec.* **2007**, *7*, 125. (b) Wang, Y.; Raabe, G.; Reppges, C.; Fleischhauer, J. *Int. J. Quantum Chem.* **2003**, *93*, 265. (c) Marié, J.-C.; Xiong, Y.; Min, G. K.; Yeager, A. R.; Taniguchi, T.; Berova, N.; Schaus, S. E.; Porco, J. A., Jr. *J. Org. Chem.* **2010**, *75*, 4584. (d) He, Y.; Wang, B.; Dukor, R. K.; Nafie, L. A. *Appl. Spectrosc.* **2011**, *65*, 699. (e) Cheeseman, J. R.; Frisch, M. J.; Devlin, F. J.; Stephens, P. J. *Chem. Phys. Lett.* **1996**, *252*, 211.

(21) (a) Weiß, R.; Wagner, K.-G. *Chem. Ber.* **1984**, *117*, 1973.

(b) Karadogan, B.; Parsons, P. J. *Tetrahedron* **2001**, *57*, 8699.

(22) CCDC 1499681 (10) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre.

(23) (a) Soai, K.; Ookawa, A. *J. Org. Chem.* **1986**, *51*, 4000. (b) Soai, K.; Oyamada, H.; Takase, M.; Ookawa, A. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 1948.

(24) (a) Kim, J. N.; Ryu, E. K. *Tetrahedron Lett.* **1993**, *34*, 8283.

(b) Kim, J. N.; Jung, K. S.; Lee, H. J.; Son, J. S. *Tetrahedron Lett.* **1997**,

38, 1597. (c) Bhat, V.; Allan, K. M.; Rawal, V. H. *J. Am. Chem. Soc.* **2011**, *133*, 5798.

(25) Schoepfer, J.; Marquis, C.; Pasquier, C.; Neier, R. *J. Chem. Soc., Chem. Commun.* **1994**, 0, 1001.

(26) While CH₃CN as a solvent provided similar solubility and reactivity, it was not employed because of the formation of the Ritter-type reaction product (2,4,4,5-tetramethyl-4,5-dihydrooxazole), which disturbed the purification process.